<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57167">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098733</url>
  </required_header>
  <id_info>
    <org_study_id>097-011</org_study_id>
    <nct_id>NCT02098733</nct_id>
  </id_info>
  <brief_title>Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of of long-term use of
      Sonias Combination Tablets in patients with type 2 diabetes mellitus in the routine clinical
      setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a special drug use surveillance on long-term use of  pioglitazone/glimepiride
      combination tablets (Sonias Combination Tablets) designed to investigate the frequency of
      adverse drug reactions in patients with type 2 diabetes mellitus in the routine clinical
      setting.

      The usual adult dosage is one tablet of Sonias administered orally once daily before or
      after breakfast (15 mg/1 mg or 30 mg/3 mg of pioglitazone/glimepiride).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Frequency of adverse drug reactions</measure>
    <time_frame>For 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency, seriousness, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tabulation of HbA1c values and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting blood glucose level</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tabulation of fasting blood glucose level and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fasting insulin level</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tabulation of fasting insulin level and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1168</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone/glimepiride</arm_group_label>
    <description>Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone/glimepiride</intervention_name>
    <description>Pioglitazone/glimepiride combination tablets</description>
    <arm_group_label>Pioglitazone/glimepiride</arm_group_label>
    <other_name>Sonias combination tablets</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus for whom a physician has concluded that
             combination therapy with pioglitazone hydrochloride and glimepiride is appropriate
             and for whom long-term treatment with Sonias Combination Tablets is considered
             necessary

        Exclusion Criteria:

          -  (1) Patients with cardiac failure or a history of cardiac failure (2) Patients with
             serious hepatic or renal impairment (3) Patients with severe ketosis, diabetic coma
             or precoma, or type 1 diabetes mellitus (4) Patients with severe infection, severe
             trauma, or pre- and post-operative patients (5) Patients with gastrointestinal
             disorders such as diarrhea and vomiting (6) Pregnant or potentially pregnant women
             (7) Patients with a history of hypersensitivity to the ingredients in Sonias
             Combination Tablets or sulfonamides
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
